Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12109792 | 0.77 | CYP3A4 (0.34) | MEN1ALDH1A1LMNAHPGDKMT2A | |
| SCHEMBL14683279 | 0.77 | — | — | |
| SCHEMBL1249626 | 0.74 | PIK3CD (0.32) | EGFR | |
| SCHEMBL2642236 | 0.73 | ACHE (0.42) | ACHECYP4F2CYP4A11KDM4ECASP6 | |
| SCHEMBL604311 | 0.73 | ERN1 (0.41) | ERN1CA12CA1CA9 | |
| SCHEMBL4420463 | 0.73 | ALDH1A1 (0.44) | ACHEERN1KDM4ECASP6MEN1 | |
| SCHEMBL10705397 | 0.73 | KDM4E (0.39) | ACHEERN1KDM4ECASP6MEN1 | |
| SCHEMBL23785511 | 0.72 | CYP3A4 (0.34) | KDM4E | |
| SCHEMBL22437205 | 0.72 | IGF1R (0.37) | ERN1MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL11886147 | 0.72 | CYP4F2 (0.42) | ERN1CYP4F2CYP4A11KIF11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4243816-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022104206-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104206-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20180078541-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, NUAK1, NUAK2 | ACHE 1060/4885ERN1 525/4885CYP4F2 4634/4885 |
| US-20180078541-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | FPR2, FPR1, FPR3 | ACHE 3031/4885ERN1 3801/4885CYP4F2 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.